Table 1.
Demographic and clinical characteristics of 101 patients
| Characteristic | Total,n(%)/mean or median(range) |
|---|---|
| Age(years) | 55(36-76) |
| Primary site of disease | |
| Ovary | 94(93.1) |
| Peritoneum | 4(4.0) |
| Fallopian tube | 3(3.0) |
| FIGO Stage | |
| III | 88(87.1) |
| IV | 13(12.9) |
| Tumor Grade | |
| G1 | 3(3.0) |
| G2 | 11(10.9) |
| G3 | 84(83.1) |
| UnKnown | 3(3.0) |
| Histology | |
| Serous | 85(84.2) |
| Endometrioid | 3(3.0) |
| Clear cell | 6(5.9) |
| Mucinous | 1(1.0) |
| Others | 6(5.9) |
| CA125 presentation (U/ml) | 1952.0(56.6-56541.0) |
| CA125 preoperatively (U/ml) | 269.0(36.8-10971.0) |
| CA125 after 1st CT postop (U/ml) | 44.80(7.0-1266.0) |
| CA125 after 2nd CT postop (U/ml) | 27.2(3.8-935.1) |
| CA125 after 3rd CT postop (U/ml) | 19.1(0.6-545.1) |
| CA125 relative change preop to 1st CT postop (%) | 77.2(-62.6-99.6) |
| CA125 relative change preop to 2nd CT postop (%) | 89.7(-27.80-99.9) |
| CA125 relative change preop to 3rd CT postop (%) | 91.8(-160.33-99.9) |
| Nadir (U/ml) | 12.6(0.6-545.1) |
| Time to Normalization (day) | 94.0(40.0-811.0) |
| Time to nadir (day) | 161.0(44.0-433.0) |
| CA125 half-life (day) | 15.9(4.8-270.9) |
| Residual disease | |
| No visible residual | 30(29.7) |
| Residual disease≤2cm | 54(53.5) |
| Residual disease>2cm | 17(16.8) |
| Chemotherapy cycles | |
| 6-8 | 70(69.3) |
| >8 | 31(30.7) |
FIGO: federation of gynecology and obstetrics; CT: chemotherapy; Postop: postoperatively; Preop: preoperatively